Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Moderna And Merck To Collaborate
by Rick Mullin
January 19, 2015
| A version of this story appeared in
Volume 93, Issue 3
Moderna followed the announcement earlier this month of a $450 million venture capital funding round, the largest ever in the biotech sector, with news of a licensing and collaboration agreement with Merck & Co. The new partners are joining to develop messenger RNA-based vaccines and therapies for viral diseases. Merck will pay $50 million for the ability to commercialize five drug candidates and will make a $50 million investment in Moderna. Moderna also will be eligible for milestone payments.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter